・UKBBの条文（英）
  ・1 . Supply of Materials by UK Biobank

・UKBBの条文（英）
  ・1.1 UK Biobank agrees to supply the Materials to the Applicant in the timeframe and manner set out in this MTA, subject to the provisions of this MTA.

・UKBBの条文（英）
  ・1.2 UK Biobank warrants to the Applicant that for the purposes of this MTA:

・UKBBの条文（英）
  ・1.2.1 it is entitled to supply the Materials to the Applicant;

・UKBBの条文（英）
  ・1.2.2 consent to take part in UK Biobank has been obtained from the Participants and further, consent under the Human Tissue Act 2004, has been obtained from the relevant Participants; and

・UKBBの条文（英）
  ・1.2.3 the use of the Materials for the Approved Research Project falls within UK Biobank's generic Research Tissue Bank (RTB) approval from the NHS North West REC, available here.

・UKBBの条文（英）
  ・1.3 The Applicant agrees that the Materials are provided on an "as is" basis without any warranty of satisfactory quality or fitness for a particular purpose or use, or that use of the Materials shall not infringe the rights of any third party. Except as expressly stated in this MTA, all warranties, terms and conditions, whether express or implied by statute, common law or otherwise, are excluded to the fullest extent permitted by law.

・UKBBの条文（英）
  ・2 . Usage of Materials by the Applicant

・UKBBの条文（英）
  ・2.1 The Applicant agrees that the Materials:

・UKBBの条文（英）
  ・2.1.1 shall only be used in accordance with the terms and conditions of this MTA;

・UKBBの条文（英）
  ・2.1.2 shall only be used to conduct the Approved Research Project for the Permitted Purpose only;

・UKBBの条文（英）
  ・2.1.3 shall not be used for any purpose connected with prohibited weapons (including biological weapons), and shall not be transferred if it is known or suspected that they are intended or likely to be used for such purposes;

・UKBBの条文（英）
  ・2.1.4 shall not be transferred to a destination subject to a UN, EU, UK or OSCE embargo where that act would be in breach of the terms of that embargo; and

・UKBBの条文（英）
  ・2.1.5 shall only be used by the Applicant institution and on an individual level within the Applicant, by the Applicant Pl, the Applicant Researchers and by Affiliates and Third-Party Processors (appointed by the Applicant).

・UKBBの条文（英）
  ・2.2 The Applicant shall not share, sub-license, disclose, transfer, sell, gift or supply the Materials to any other person or unauthorised third party.

・UKBBの条文（英）
  ・2.3 Without prejudice to the other provisions of this MTA, any actual or anticipatory breach of any provision of clauses 2.1 or 2.2 shall entitle UK Biobank to terminate this Agreement with immediate effect and require the immediate return or destruction of any Materials provided by UK Biobank.

・UKBBの条文（英）
  ・2.4 The Applicant shall and shall procure cure that the Applicant Pl, the Applicant Researchers and any Affiliate and any Third-Party Processors are made aware of, and shall comply with, the terms and conditions of this MTA and the Data Protection Legislation. Any act or omission of the Applicant Pl or any Applicant Researcher or any Affiliate or any Third-Party Processor shall be deemed to be an act of the relevant Applicant for which the relevant Applicant is fully responsible and liable.

・UKBBの条文（英）
  ・2.5 This MTA confers on the Applicant only those rights that are expressly granted to the Applicant.

・UKBBの条文（英）
  ・2.6 In relation to the Materials supplied to the Applicant:

・UKBBの条文（英）
  ・2.6.1 UK Biobank is the owner of the Materials, and UK Biobank is the owner of the Intellectual Property Rights in the Materials; and

・UKBBの条文（英）
  ・2.6.2 UK Biobank hereby grants to the Applicant a revocable, worldwide, royalty-free, non-exclusive, non-transferable licence (but not any ownership rights) during the Term to use the Materials for the Permitted Purpose, subject to the terms and conditions of this MTA.

・UKBBの条文（英）
  ・3 . Generation of data by the Applicant

・UKBBの条文（英）
  ・3.1 The data generated by the Applicant in the performance of the Approved Research Project shall be deemed to fall into the following categories:

・UKBBの条文（英）
  ・3.1.1 Results Data: data and methodology (for example, the SAS/R/Stata scripts) which underlie the Findings, and which would enable another competent researcher to generate the Findings;

・UKBBの条文（英）
  ・3.1.2 Findings: the findings generated by the Applicant as a result of the Approved Research Project; and/or

・UKBBの条文（英）
  ・3.1.3 Other Data: all other data generated by the Applicant which is not in one of the above two categories.

・UKBBの条文（英）
  ・3.2 Except as provided in clause 3.3, the Applicant shall own the IPRs in their Findings, the Results Data and the Other Data. The Applicant hereby grants a perpetual, irrevocable, worldwide, fully paid up, royalty free, fully sub-licensable non-exclusive licence to UK Biobank to use, reproduce, distribute, publish, store and otherwise disseminate the Findings, the Results Data and the Other Data.

・UKBBの条文（英）
  ・3.3 Nothing in this MTA shall operate to assign to the Applicant any IPRs in the Materials.

・UKBBの条文（英）
  ・3.4 The Applicant confirms to UK Biobank that UK Biobank's receipt of and use of the Applicant's Findings and Results Data shall not infringe the rights, including any existing IPRS, of any third party. Such confirmation shall be:

・UKBBの条文（英）
  ・3.4.1 deemed to be taken at the time, respectively, of the publication of the Findings or the return of the Results Data to UK Biobank; and

・UKBBの条文（英）
  ・3.4.2 given to the best of the Applicant's knowledge and belief, having made reasonable and diligent enquiry (but the extent of this obligation does not include any requirement on the Applicant to conduct external patent searches).

・UKBBの条文（英）
  ・3.5 Subject always to the restriction in clause 3.7, UK Biobank confirms that it shall have no rights or licence to the IPRs in relation to any inventions made by the Applicant as a result of using the Materials, Results Data, Findings or Other Data ("Applicant-Generated Inventions").

・UKBBの条文（英）
  ・3.6 However, the Applicant acknowledges that the UK Biobank resource has been produced using a combination of the goodwill and contribution of 500,000 UK participants, charitable and public funding, the use of public resources (such as UK health-record data) and established with the express purpose of promoting the conduct of health-related research which is in the public interest.

・UKBBの条文（英）
  ・3.7 Taking into account the acknowledgements in clause 3.6, the Applicant agrees that it shall not and shall not attempt to:

・UKBBの条文（英）
  ・3.7.1 file any patents with claims directed to; or

・UKBBの条文（英）
  ・3.7.2 otherwise seek to claim or enforce any IPRs in; * the genotype-phenotype data within the Materials or in the genotype-phenotype data which has been generated by the Applicant in the course of the Approved Research Project.

・UKBBの条文（英）
  ・3.8 UK Biobank expressly excludes any right of the Applicant to sub-licence any of the rights granted to the Materials under this MTA or to publish or distribute any of the Materials, except for the sole purpose of including a commensurate amount of supporting data in the Applicant's publication of its Findings.

・UKBBの条文（英）
  ・3.9 For the avoidance of doubt, the rights granted under this MTA to the Applicant to use the Materials are for the Permitted Purpose only.

・UKBBの条文（英）
  ・4 . Confirmations from the Applicant

・UKBBの条文（英）
  ・4.1 The Applicant confirms to UK Biobank that all work performed by it using the Materials shall be carried out in compliance with:

・UKBBの条文（英）
  ・4.1.1 all applicable laws, regulations, guidelines and approvals, including without limitation the Human Tissue Act 2004, the Data Protection Legislation and any approvals required from a Research Ethics Committee (or the applicable equivalent in the jurisdiction where the Approved Research Project is to be conducted); and

・UKBBの条文（英）
  ・4.1.2 all applicable trade restrictions and export controls, including without limitation all sanctions, meaning those trade, economic and financial sanctions laws, regulations, embargoes, and restrictive measures (in each case having the force of law) administered, enacted or enforced from time to time by (i) the United Kingdom; (ii) the United States; (iii) the European Union and its Member States; (iv) the United Nations; or (v) other governments.

・UKBBの条文（英）
  ・4.2 The Applicant shall retain the Materials in a secure network system, at a standard which would be reasonably expected for the storage of valuable and proprietary sensitive/confidential data. In addition, the Applicant shall be obliged to implement the appropriate technical and organisational measures as set out in Annex 2 (Security Measures) to protect the Materials from the accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to the Materials (a "Data Security Incident"). By signing this MTA, the Applicant Pl confirms that the Security Measures set out in Annex 2 are in place in order to protect the Materials.

・UKBBの条文（英）
  ・4.3 The Applicant shall notify UK Biobank without undue delay (and in any event no later than 24 hours) after becoming aware of a reasonably suspected "near miss" or actual Data Security Incident which affects the Materials. Such notification must be sent by email to DPO@ukbiobank.ac.uk with a copy to access@ukbiobank.ac.uk.

・UKBBの条文（英）
  ・4.3.1 The Applicant shall not delay such notification on the basis that the information is incomplete, or the relevant investigation is ongoing. Further, the Applicant shall not make any external announcement, notifications to a supervisory authority or regulator about any such Data Security Incident without the express prior written consent of UK Biobank, unless required by law to do so.

・UKBBの条文（英）
  ・4.3.2 Both parties shall cooperate and provide reasonable assistance to each other to facilitate the handling of the Data Security Incident.

・UKBBの条文（英）
  ・4.4 The Applicant confirms that it shall deal promptly and appropriately (in accordance with the Participants option to withdraw as set out on the UK Biobank website here) with any "no further use" withdrawals by Participants which UK Biobank notifies to the Applicant.

・UKBBの条文（英）
  ・4.5 The Applicant is expressly prohibited from (or attempting to):

・UKBBの条文（英）
  ・4.5.1 developing, linking or re-engineering the Materials supplied to it so as to identify (directly or indirectly) any Participant;

・UKBBの条文（英）
  ・4.5.2 identifying any Participant from the Materials provided by UK Biobank; or

・UKBBの条文（英）
  ・4.5.3 contacting any Participant.

・UKBBの条文（英）
  ・4.6 In the event that the Applicant inadvertently identifies any Participant then it shall notify UK Biobank immediately setting out (in reasonable detail) the circumstances by which it happened. Such notification must be sent by email to DPO@ukbiobank.ac.uk with a copy to access@ukbiobank.ac.uk.

・UKBBの条文（英）
  ・4.7 Other than for the purposes of clause 4.6, the Applicant shall not:

・UKBBの条文（英）
  ・4.7.1 share the identification of that Participant with any other person; or

・UKBBの条文（英）
  ・4.7.2 attempt to contact the Participant themselves.

・UKBBの条文（英）
  ・4.8 Without prejudice to the other provisions of this MTA, any actual or anticipatory breach of any provision of clauses 4.1, 4.2 and 4.4 to 4.7 inclusive shall entitle UK Biobank to terminate this Agreement with immediate effect and require the immediate return or destruction of any Materials provided by UK Biobank.

・UKBBの条文（英）
  ・5 . Publication of lay summary, submission of annual report and return and publication of Findings

・UKBBの条文（英）
  ・5.1 After the Applicant has received the Materials for the Approved Research Project, UK Biobank shall be entitled to publish on its website:

・UKBBの条文（英）
  ・5.1.1 the lay summary of the Approved Research Project contained in the Application (with the exception of any material that has been agreed by UK Biobank would be kept confidential); and

・UKBBの条文（英）
  ・5.1.2 summary details of the Applicant.

・UKBBの条文（英）
  ・5.2 During the Term, the Applicant shall provide UK Biobank with:

・UKBBの条文（英）
  ・5.2.1 a report (with a summary section) setting out in reasonable detail the progress of the Approved Research Project in the form attached as Annex 3 (or in such other format as required by UK Biobank from time to time) on an annual basis (from the Effective Date) which shall include the Findings the Applicant has made which in its reasonable view may be: * (a) published or pending publication; * (b) disclosed in a published patent; or * (c) otherwise of significance (in the context of medical research); and

・UKBBの条文（英）
  ・5.2.2 a summary (and a copy of the application if requested) of any patents whose claims cover, or are intended to cover, an Applicant-Generated Invention within two (2) months of their publication.

・UKBBの条文（英）
  ・5.3 In relation to the Annual Project Report, UK Biobank:

・UKBBの条文（英）
  ・5.3.1 shall have the ability to make the summary section of the Annual Project Report public, subject to the Applicant (as referred to in clause 5.7 below) retaining a reasonable period of confidentiality on items where patent rights still need to be filed; and

・UKBBの条文（英）
  ・5.3.2 shall have the opportunity to ask the Applicant any reasonable questions arising from the Annual Project Report and the Applicant shall respond to such questions in a timely manner.

・UKBBの条文（英）
  ・5.4 If the Annual Project Report, or any other information or data provided to UK Biobank, contains any technology or data that is subject to applicable export controls, it shall be the responsibility of the Applicant to obtain any export licence that may be required to authorise the transmission of the Annual Project Report, information or data to UK Biobank. The Applicant shall notify UK Biobank at least one week in advance that an Annual Project Report, information or data is to be sent under an export licence and shall provide UK Biobank with full details of the conditions of the licence and of the reasons for the control of the technology contained in the Annual Project Report, information or data.

・UKBBの条文（英）
  ・5.5 In the event that the Annual Project Report is not received by UK Biobank in the timeframe, manner and form prescribed, then the Applicant's rights under this MTA shall be suspended and the Applicant (together with any Collaborators) will not be able to download further data (either in terms of new data fields or updates of existing data fields) or access existing data via the research access platform until such time as the Annual Project Report has been duly and compliantly provided. If the Annual Project Report is still outstanding, notwithstanding reminders from UK Biobank, 3 months after the relevant anniversary of the Effective Date, then UK Biobank has the right to terminate this MTA by giving the Applicant written notice of termination and/or prevent the Applicant Institution (or Applicant PI) from applying for or accessing any further Materials from UK Biobank.

・UKBBの条文（英）
  ・5.6 The Applicant shall use All Reasonable Endeavours to publish the Findings (and provide UK Biobank with a link thereto) within six (6) months after the Completion Date for the Approved Research Project:

・UKBBの条文（英）
  ・5.6.1 in an academic journal; or

・UKBBの条文（英）
  ・5.6.2 on an open-source publication site.

・UKBBの条文（英）
  ・5.7 UK Biobank acknowledge and agree that the Applicant may keep such Findings confidential for a reasonable time in accordance with its reasonable research and development practices. For the avoidance of doubt, the Applicant is entitled to retain confidentiality regarding any Finding over which patent protection is being sought (and the patent has not yet been published).

・UKBBの条文（英）
  ・5.8 If such Findings are made publicly available, UK Biobank requires that the Results Data underlying such Findings shall be promptly returned or otherwise made available to UK Biobank. UK Biobank also requires that the Results Data are returned in a format which is appropriate and comprehensible (particularly for other researchers) along with any documentation which would be reasonably necessary to enable another researcher to interpret and understand the Results Data.

・UKBBの条文（英）
  ・5.9 Within six (6) months after the publication of the Findings, the relevant Applicant shall provide to UK Biobank the Results Data in such form and format as set out in clause 5.8 above (alternatively UK Biobank and the relevant Applicant may agree that the relevant Applicant retains the Results Data on the basis that they are made publicly available to other Researchers and/or publicly available generally).

・UKBBの条文（英）
  ・5.10 UK Biobank shall consider reasonably any written requests (containing an appropriate explanation) for an extension of the time limits set out in this clause.

・UKBBの条文（英）
  ・5.11 The Applicant shall use All Reasonable Endeavours to publish a commensurate level of Findings in relation to the Approved Research Project within the first three (3) years of the Term (and in any subsequent extensions). Where this is not possible, the Applicant shall provide UK Biobank with a reasonable explanation as to why it is not possible and an estimation of when a publication can be expected.

・UKBBの条文（英）
  ・5.12 Unless otherwise stated in Annex 4, the Applicant is not required to obtain UK Biobank's approval to any report of its Findings. The Applicant shall nevertheless provide a copy of any report of its Findings and any press release to UK Biobank at least two (2) weeks before their expected date of first public presentation or publication in any format (e.g., paper journal, on-line report, meeting abstract). The Applicant shall upload such documents to AMS in the first instance. If this is not possible, the Applicant shall email such documents to access@ukbiobank.ac.uk.

・UKBBの条文（英）
  ・5.13 However, and notwithstanding the provisions of clause 5.12 above, the Applicant is required to promptly notify UK Biobank in advance (in writing) if any report of its Findings is reasonably likely to provoke controversy or otherwise attract significant public attention. In such circumstances, UK Biobank reserves the right to make such recommendations, reservations or suggestions on the report as it sees fit (and which it may make public) for consideration by the Applicant.

・UKBBの条文（英）
  ・5.14 UK Biobank requires that the term "UK Biobank" is incorporated within the title and/or the abstract of any and all publications.

・UKBBの条文（英）
  ・5.15 UK Biobank requires that any and all publications of Findings using UK Biobank data include the following credit, which should be incorporated within the "Acknowledgements" of such publication: "This research has been conducted using the UK Biobank Resource under application number [ ]."

・UKBBの条文（英）
  ・5.16 This acknowledgement to UK Biobank should, when possible, be linked to reference search tools (such as PubMed and MEDLINE and/or DOI reference).

・UKBBの条文（英）
  ・6 . Charges

・UKBBの条文（英）
  ・6.1 The Applicant agrees to pay the Access Charges as set out in the payment section of the Applicant's Application to UK Biobank via bank transfer or Sage Pay, and in British pounds sterling (GBP). The Access Charges are stated to be exclusive of VAT. The Applicant shall pay any applicable VAT in addition to the Access Charges.

・UKBBの条文（英）
  ・6.2 When paying the Access Charges, the Applicant shall quote the invoice number and/or Application Reference Number as the payment reference, and also send a remittance note to creditcontrol@ukbiobank.ac.uk.

・UKBBの条文（英）
  ・6.3 The rights granted to the Applicant by UK Biobank under this MTA are conditional on the Access Charges (and applicable VAT) being paid and so, for the avoidance of doubt, no Materials shall be provided to the Applicant until or unless the Access Charges (and applicable VAT) are received in full.

・UKBBの条文（英）
  ・6.4 If payment of the Access Charges (and applicable VAT) has not been made within ninety (90) days of receipt of this MTA by the Applicant, the Applicant shall be required to re-apply for access to the UK Biobank resource and Materials.

・UKBBの条文（英）
  ・7 . Annual Confirmation and Audit

・UKBBの条文（英）
  ・7.1 During the Term, UK Biobank requires the Applicant Pl to confirm on an annual basis that the Approved Research Project remains compliant with the provisions of the MTA (and the Annexes). Specifically, the Applicant PI shall provide UK Biobank with such confirmation as part of the Annual Project Report in the form attached at Annex 3. In the event that the Annual Project Report is not received by UK Biobank in the timeframe, manner and form prescribed, UK Biobank reserves the rights set out in clause 5.5 above.

・UKBBの条文（英）
  ・7.2 In circumstances where UK Biobank reasonably believes that a Data Security Incident or other serious incident has occurred then, on notice to the Applicant, in order to confirm or investigate compliance with the provisions of this MTA, UK Biobank may itself or via appropriate third parties:

・UKBBの条文（英）
  ・7.2.1 choose to undertake an audit (either in person or remotely) in order to review the security, storage or other arrangements for the Materials; and

・UKBBの条文（英）
  ・7.2.2 request such additional information about the Approved Research Project and/or its progress as UK Biobank may, from time to time, reasonably require.

・UKBBの条文（英）
  ・7.3 UK Biobank shall bear the costs of such audits unless a material default within the procedures and processes of the relevant Applicant is discovered, in which case the relevant Applicant shall be obliged to reimburse the reasonable costs of UK Biobank and any relevant third parties.

・UKBBの条文（英）
  ・7.4 UK Biobank confirms that its audit rights shall be exercisable no more than once a year and on the provision of reasonable notice (which may be immediate in the event of a Data Security Incident or other serious incident) to the Applicant. As far as practically possible, UK Biobank agrees to coordinate any site visits and audits with the other relevant parties.

・UKBBの条文（英）
  ・8 . Confidentiality
  ・対応するEGAの条文（英）
    ・2 . The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data.
      ・UKBBの条文とEGAの条文の内容の比較結果（一致、部分一致、不一致）(部分一致)
      ・判断理由（日）
        ・共通キーワード: なし。キーワードの重複が乏しい。

・UKBBの条文（英）
  ・8.1 Subject to the exceptions in clause 8.2, UK Biobank shall keep confidential any information disclosed to it in writing by the Applicant that is marked confidential ("Applicant's Confidential Information") and shall not disclose such information to any person.
  ・対応するNIHの条文（英）
    ・7 . Data Ownership; Confidentiality * a. All Data is and shall remain the sole and exclusive property of Registry. No ownership rights in or to the Data are transferred to Researcher hereunder. * b. Researcher agrees that it will not disclose to others or use for its own benefit or the benefit of others, any Data or other Confidential Information disclosed by Registry in the course of this Agreement. For purposes of this Agreement, "Confidential Information" shall mean methods, processes, know-how, policies, procedures, templates, and other non-public confidential information of Registry. All Confidential Information is and shall remain the confidential property of Registry. Researcher shall keep the Confidential Information in strict confidence and may not use or otherwise disclose the Confidential Information to any third party without the prior written consent of Registry. Researcher shall notify Registry within [insert timeframe, e.g., two (2) business days] of any uses or disclosures of Confidential Information not permitted by this Agreement. * c. [May consider adding language about publicity/use of each party's names, e.g., if Registry wants to publicize the fact that Researcher is accessing/using the Data]. * d. [If inventions are contemplated, may consider adding applicable invention ownership/rights language.]
      ・UKBBの条文とEGAの条文の内容の比較結果（一致、部分一致、不一致）（部分一致）
      ・判断理由（日）
        ・共通キーワード: confidential, information, disclose。主要概念の重複が多い。

・UKBBの条文（英）
  ・8.2 UK Biobank may disclose the Applicant's Confidential Information where expressly permitted by this MTA or when:
  ・対応するNIHの条文（英）
    ・7 . Data Ownership; Confidentiality * a. All Data is and shall remain the sole and exclusive property of Registry. No ownership rights in or to the Data are transferred to Researcher hereunder. * b. Researcher agrees that it will not disclose to others or use for its own benefit or the benefit of others, any Data or other Confidential Information disclosed by Registry in the course of this Agreement. For purposes of this Agreement, "Confidential Information" shall mean methods, processes, know-how, policies, procedures, templates, and other non-public confidential information of Registry. All Confidential Information is and shall remain the confidential property of Registry. Researcher shall keep the Confidential Information in strict confidence and may not use or otherwise disclose the Confidential Information to any third party without the prior written consent of Registry. Researcher shall notify Registry within [insert timeframe, e.g., two (2) business days] of any uses or disclosures of Confidential Information not permitted by this Agreement. * c. [May consider adding language about publicity/use of each party's names, e.g., if Registry wants to publicize the fact that Researcher is accessing/using the Data]. * d. [If inventions are contemplated, may consider adding applicable invention ownership/rights language.]
      ・UKBBの条文とEGAの条文の内容の比較結果（一致、部分一致、不一致）（部分一致）
      ・判断理由（日）
        ・共通キーワード: confidential, disclose, information。主要概念の重複が多い。

・UKBBの条文（英）
  ・8.2.1 it is required to be disclosed by law, by any governmental or other regulatory authority, by a court or other authority of competent jurisdiction; or

・UKBBの条文（英）
  ・8.2.2 it can be shown by UK Biobank (to the Applicant's reasonable satisfaction) to have been known by UK Biobank before disclosure to it by such Applicant; or

・UKBBの条文（英）
  ・8.2.3 it was lawfully disclosed to UK Biobank by a third party who did not impose any restrictions on its disclosure; or

・UKBBの条文（英）
  ・8.2.4 the information was in (or enters into) the public domain other than by reason of a breach of this clause by UK Biobank; or

・UKBBの条文（英）
  ・8.2.5 UK Biobank and the Applicant agree, acting reasonably, that such information is trivial or obvious, or they agree in writing that such disclosure may be permitted.

・UKBBの条文（英）
  ・9 . Data Protection * Relationship of the parties

・UKBBの条文（英）
  ・9.1 The parties acknowledge that UK Biobank and the Applicant are independent controllers with respect to the Participant Level Data that is processed in accordance with this MTA, and that the Applicant shall process the Participant Level Data strictly for the Permitted Purpose. In no event shall the parties process the Participant Level Data as joint controllers.

・UKBBの条文（英）
  ・9.2 Each party shall be individually and separately responsible for complying with the obligations that apply to it as a controller under Data Protection Legislation. * Cooperation

・UKBBの条文（英）
  ・9.3 In the event that the Applicant, Applicant PI or any Applicant Researcher receives any correspondence, enquiry or complaint from a Participant, regulator or other third party ("Correspondence") in connection with the processing of the Participant Level Data, it shall promptly inform UK Biobank giving full details of the same. In all circumstances, the Applicant, Applicant PI or any Applicant Researcher shall: (i) obtain UK Biobank's written approval before responding to the Correspondence, including approval of the contents of any response; and (ii) subject to Data Protection Legislation, permit UK Biobank to respond directly to the Correspondence. * Where the Applicant is located outside of the UK

・UKBBの条文（英）
  ・9.4 Where UK Biobank transfers Participant Level Data to an Applicant outside the UK to a territory that has not been specified as ensuring an adequate level of protection in accordance with Data Protection Legislation, the parties agree that the UK Addendum shall be automatically incorporated into this MTA by reference and deemed to be completed as set out in Part B of Annex 1 of this MTA.

・UKBBの条文（英）
  ・9.5 If there is any conflict between the MTA and the UK Addendum, the UK Addendum will prevail. * International transfers by the Applicant

・UKBBの条文（英）
  ・9.6 The Applicant shall not process any Participant Level Data (nor permit any Participant Level Data to be processed) in a territory outside of the UK (or where clause 9.4 applies, where processing occurs in a subsequent territory) unless it has taken such measures as are necessary to ensure the transfer is in compliance with Data Protection Legislation.

・UKBBの条文（英）
  ・10 . Limitation of Liability
  ・対応するNIHの条文（英）
    ・4 . Limitation of Liability * [May consider including a cap on liability/damages].
      ・UKBBの条文とEGAの条文の内容の比較結果（一致、部分一致、不一致）（一致）
      ・判断理由（日）
        ・共通キーワード: liability, limitation。一部のキーワードが一致。

・UKBBの条文（英）
  ・10.1 The parties agree that:

・UKBBの条文（英）
  ・10.1.1 subject to clauses 10.2, 10.3 and 10.4, UK Biobank’s maximum aggregate Liability under this MTA and/or in relation to the Approved Research Project shall be limited to the Access Charges paid or payable by the Applicant to UK Biobank (whether or not invoiced to the Applicant) in relation to the Approved Research Project; and

・UKBBの条文（英）
  ・10.1.2 subject to clauses 10.2, 10.3 and 10.5, the Applicant's maximum aggregate Liability under this MTA and/or in relation to the Approved Research Project shall be limited to the Access Charges paid or payable by the Applicant to UK Biobank (whether or not invoiced to the Applicant) in relation to the Approved Research Project.

・UKBBの条文（英）
  ・10.2 Notwithstanding clause 10.1 above, UK Biobank shall have no Liability to the Applicant and the Applicant shall have no Liability to UK Biobank for any:

・UKBBの条文（英）
  ・10.2.1 loss of profit (whether direct, indirect or consequential);

・UKBBの条文（英）
  ・10.2.2 loss of use, loss of revenue, loss of production or loss of business (in each case whether direct, indirect or consequential);

・UKBBの条文（英）
  ・10.2.3 loss of goodwill, loss of reputation or loss of opportunity (in each case whether direct, indirect or consequential);

・UKBBの条文（英）
  ・10.2.4 loss of anticipated savings or loss of margin (in each case whether direct, indirect or consequential);

・UKBBの条文（英）
  ・10.2.5 loss of use or value of any data or software (in each case whether direct, indirect or consequential); or

・UKBBの条文（英）
  ・10.2.6 indirect or consequential loss.

・UKBBの条文（英）
  ・10.3 Nothing in this MTA shall operate to exclude or limit any Liability which cannot legally be limited including but not limited to liability for:

・UKBBの条文（英）
  ・10.3.1 death or personal injury caused by negligence;

・UKBBの条文（英）
  ・10.3.2 for its fraud or fraudulent misrepresentation; and

・UKBBの条文（英）
  ・10.3.3 for any matter for which it is not permitted by law to exclude or limit, or to attempt to exclude or limit, its Liability.

・UKBBの条文（英）
  ・10.4 For the avoidance of doubt, UK Biobank shall have no responsibility or Liability (including but without limitation any product-related Liability) for any finding, product, test or treatment developed directly or indirectly by the Applicant using the Materials.

・UKBBの条文（英）
  ・10.5 Nothing in this MTA shall operate to exclude or limit the Applicant’s Liability to UK Biobank for any loss, damage, costs or expenses arising from:

・UKBBの条文（英）
  ・10.5.1 the Applicant’s failure to comply with clause 9 (Data Protection) and clauses 14.5 to 14.10 inclusive (Third-Party Processors);

・UKBBの条文（英）
  ・10.5.2 any breach of clause 2.2 or any circumstance in which the Applicant sub-licenses, distributes or otherwise shares the Materials (including any IPRs) with any unauthorised person or third party;

・UKBBの条文（英）
  ・10.5.3 any circumstance set out in clauses 4.5 and 4.7; and

・UKBBの条文（英）
  ・10.5.4 any Data Security Incident which is caused by the Applicant.

・UKBBの条文（英）
  ・11 . Term

・UKBBの条文（英）
  ・11.1 The term of this MTA shall commence on the Effective Date and shall end on the Completion Date unless terminated sooner in accordance with clause 12 or in accordance with law.

・UKBBの条文（英）
  ・11.2 The Term of this MTA may be extended by the Applicant (and with the agreement of UK Biobank) during the final year of the Approved Research Project in the following one (1) year increments:

・UKBBの条文（英）
  ・11.2.1 for a minimum of period of one (1) year;

・UKBBの条文（英）
  ・11.2.2 for a period of two (2) years; or

・UKBBの条文（英）
  ・11.2.3 for a maximum period of three (3) years; * on application to UK Biobank setting out (in reasonable detail) the reasons for the extension request and subject to the payment of the relevant further Access Charges.

・UKBBの条文（英）
  ・11.3 For the avoidance of doubt, the extensions set out in clause 11.2 above can be applied cumulatively (subject to applicable Access Charges) so that, for example, an extension of 3 years may be granted to take the Approved Research Project duration from 3 years to 6 years, and this may then be extended by a further 3 years to 9 years and so on.

・UKBBの条文（英）
  ・12 . Termination and consequences of termination

・UKBBの条文（英）
  ・12.1 UK Biobank shall be entitled to terminate this MTA immediately by written notice to the Applicant if the Applicant:

・UKBBの条文（英）
  ・12.1.1 commits any breach of a material provision of this MTA or a material breach of this MTA, and, in the case of a breach capable of remedy, fails to remedy the same within 10 days after receipt of a written notice giving particulars of the breach and requiring it to be remedied; or

・UKBBの条文（英）
  ・12.1.2 ceases, is likely to cease, or threatens to cease carrying on business or suffers an Insolvency Event, or is subject to a serious, adverse regulatory finding.

・UKBBの条文（英）
  ・12.2 Upon expiry of the MTA pursuant to clause 11.1 above or termination of this MTA by UK Biobank pursuant to clause 12.1 or in accordance with law:

・UKBBの条文（英）
  ・12.2.1 the grant of rights and all licences to the Applicant under this MTA shall be automatically terminated; and

・UKBBの条文（英）
  ・12.2.2 the Applicant shall destroy the Materials or otherwise render them permanently inaccessible and confirm in writing to access@ukbiobank.ac.uk that this has been done. For the avoidance of doubt, the Applicant shall not be required to destroy Results Data or Other Data subject to the provisions of this MTA being complied with.

・UKBBの条文（英）
  ・12.3 Without prejudice to the foregoing and to any other rights or remedies that UK Biobank may have, UK Biobank may take the following steps if there is a breach that entitles UK Biobank to terminate this MTA under clause 12.1:

・UKBBの条文（英）
  ・12.3.1 it may prohibit the Applicant PI, Applicant Researchers and any other researchers from the Applicant Institution from accessing any further Materials from within the UK Biobank resource for an indefinite period of time; and/or

・UKBBの条文（英）
  ・12.3.2 it may elect to inform the relevant personnel within the defaulting Applicant Institution, funders of the defaulting Applicant PI and/or governing or other relevant regulatory bodies.

・UKBBの条文（英）
  ・12.4 Notwithstanding termination of this MTA for any reason, the provisions of clauses 2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16 and 17 shall continue in force in accordance with their respective terms.

・UKBBの条文（英）
  ・12.5 Termination or expiry of this MTA shall not affect the rights and obligations of the parties accrued at the date or termination or expiry.

・UKBBの条文（英）
  ・13 . Notices

・UKBBの条文（英）
  ・13.1 Notices required under this MTA shall be in writing and shall be:

・UKBBの条文（英）
  ・13.1.1 sent by email to the addresses set out below; or

・UKBBの条文（英）
  ・13.1.2 (in the event of failure to deliver an email) by post to the registered address of UK Biobank or the Applicant.

・UKBBの条文（英）
  ・13.2 Any notice shall be deemed to be received:

・UKBBの条文（英）
  ・13.2.1 if sent by email, upon receipt at the recipient’s email server, (or, if this time falls outside business hours in the place of receipt, when business hours resume); or

・UKBBの条文（英）
  ・13.2.2 if sent by post, on the date of delivery if a business day in the place of receipt (or, if not a business day, on the first business day thereafter).

・UKBBの条文（英）
  ・13.3 Notices to UK Biobank shall be sent to the access team at access@ukbiobank.ac.uk. Notices to the Applicant shall be sent by email to the relevant Applicant and the Applicant PI.

・UKBBの条文（英）
  ・14 . Affiliates, assignment and sub-contracting * Affiliates

・UKBBの条文（英）
  ・14.1 The rights granted to the Applicant under this MTA for the Approved Research Project include the Affiliates of the Applicant, subject to the Applicant:

・UKBBの条文（英）
  ・14.1.1 providing updated details of each Affiliate in the Annual Project Report submitted to UK Biobank on an annual basis in accordance with clause 7.1 of the MTA;

・UKBBの条文（英）
  ・14.1.2 remaining fully liable and responsible to UK Biobank for all acts, defaults and omissions of each of its Affiliates as if they were the Applicant’s own; and

・UKBBの条文（英）
  ・14.1.3 ensuring that each of its Affiliates comply with the terms and conditions of this MTA. * Assignment

・UKBBの条文（英）
  ・14.2 Neither UK Biobank nor the Applicant shall be entitled to assign this MTA or any of its rights or obligations hereunder without first having received the written approval of the other party, such approval not to be unreasonably withheld or delayed. * Subcontracting

・UKBBの条文（英）
  ・14.3 Other than in the circumstances set out in clause 14.5, the Applicant shall not sub-contract the performance of any of its obligations under the MTA or any part thereof without having first obtained the prior written consent of UK Biobank, such consent not to be unreasonably withheld.

・UKBBの条文（英）
  ・14.4 In the event that consent is granted under clause 14.3, the relevant Applicant shall be responsible for the acts, defaults and omissions of its sub-contractors as if they were the Applicant’s own, and any consent given shall not relieve such relevant Applicant of any of its obligations under this MTA. * Third-Party Processors

・UKBBの条文（英）
  ・14.5 UK Biobank acknowledges and agrees that the Applicant may subcontract to third party processors to process the Materials strictly for the Permitted Purpose and only in relation to discrete elements of data computation and analysis (such processors being, "Third-Party Processors"). The Applicant must comply with, and only engage Third-Party Processors strictly in accordance with the terms set out in clauses 14.6 to 14.10 inclusive.

・UKBBの条文（英）
  ・14.6 The Applicant warrants that the Third-Party Processor is not a Collaborator and shall only be engaged for the purposes of discrete elements of data computation and analysis in relation to the Permitted Purpose (the "Processor Task").

・UKBBの条文（英）
  ・14.7 Prior to engaging a Third-Party Processor, the Applicant shall conduct and document the following assessment:

・UKBBの条文（英）
  ・14.7.1 whether the Third-Party Processor is necessary for the progress of the research aims of the Approved Research Project;

・UKBBの条文（英）
  ・14.7.2 whether the Third-Party Processor is a suitable recipient for the data in terms of both its provenance on past data security and past data usage / activities (for example Cambridge Analytica would not qualify); and

・UKBBの条文（英）
  ・14.7.3 whether the Third-Party Processor is able to provide sufficient assurance(s) that it shall process the Materials in a manner that will meet the requirements of Data Protection Legislation.

・UKBBの条文（英）
  ・14.8 The Applicant shall:

・UKBBの条文（英）
  ・14.8.1 remain fully responsible to UK Biobank for all acts, defaults and omissions of the Third-Party Processor as if they were the Applicant's own;

・UKBBの条文（英）
  ・14.8.2 provide only such Materials to the Third-Party Processor as is strictly necessary for the Third-Party Processor to perform the Processor Task;

・UKBBの条文（英）
  ・14.8.3 provide details of each Third-Party Processor and the Processor Task in the Annual Project Report submitted to UK Biobank on an annual basis in accordance with clause 7.1 of the MTA; and

・UKBBの条文（英）
  ・14.8.4 only engage the Third-Party Processor on the basis that a written agreement with the Third-Party Processor is executed prior to any data transfer or processing of Materials taking place. Such agreement must include inter alia: * (a) a clear definition and scope of the Processor Task, including an agreement only to process the data in accordance with the Applicant’s documented instructions; * (b) to authorise the Third-Party Processor only to undertake the Processor Task and not to perform any other act, unless expressly authorised to do so; * (c) to store, process and use the Materials to the security standards set out in the MTA (as a minimum) and implements appropriate technical and organisational security measures to protect the Materials against a Data Security Incident; * (d) to delete (or render permanently inaccessible) the Materials (and any data generated as a result of the Processor Task) once the Processor Task has been completed; * (e) to confirm that the Third-Party Processor has no rights (directly or indirectly) in either any Materials (or data derived therefrom) or from anything which the Applicant has created or done as part of the Approved Research Project (which is covered by the MTA between UK Biobank and the Applicant); * (f) to confirm that the Third-Party Processor is bound by the provisions which are equivalent to the relevant provisions in the MTA, including, but not limited to: a) not to transfer the Materials (or data derived therefrom) to any third party and b) not to make any attempt to re-identify any Participant; * (g) that the Third-Party Processor provides sufficient assurance(s) that it shall process the Materials in a manner that will meet the requirement of Data Protection Legislation; and * (h) that the Applicant has an unfettered unilateral right to terminate its agreement with the Third-Party Processor immediately if a material problem arises (including a breach by the Third-Party Processor of any of the above provisions).

・UKBBの条文（英）
  ・14.9 The Applicant must keep the activities of the Third-Party Processor under reasonable review in order to ensure compliance with clauses 14.5 to 14.10 inclusive.

・UKBBの条文（英）
  ・14.10 In the event that UK Biobank raises any concern regarding the identity of the Third-Party Processor or the activities of a Third-Party Processor, the Applicant shall investigate and report on the matter promptly. UK Biobank may require, if reasonably necessary (and subject to a dialogue with the Applicant), the Applicant to:

・UKBBの条文（英）
  ・14.10.1 to audit the Third-Party Processor; and / or

・UKBBの条文（英）
  ・14.10.2 terminate the agreement with the Third-Party Processor.
  ・対応するNIHの条文（英）
    ・8 . Term and Termination * a. Term: The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as set forth in this Section 8, shall remain in effect [may consider a specified term; e.g., set number of years, or a broader end date, e.g., until completion of the Research]. * b. Termination: Either party may terminate this Agreement upon [insert number] days prior written notice to the other party for any reason or no reason. Registry may terminate this Agreement immediately upon written notice to Researcher if Registry is no longer permitted to share the Data with Researcher. In addition, either party may terminate this Agreement upon written notice to the other party in the event of a material breach of this Agreement by the other party, which material breach is not cured within [insert number] days after receipt of written notice thereof. * c. Effect of Termination: [Insert the Registry's requirement for post-termination activities, e.g., will Data need to be returned or destroyed, can Researcher continue using the Data for a limited period].
      ・UKBBの条文とEGAの条文の内容の比較結果（一致、部分一致、不一致）（部分一致）
      ・判断理由（日）
        ・共通キーワード: なし。キーワードの重複が乏しい。

・UKBBの条文（英）
  ・15 . Force majeure

・UKBBの条文（英）
  ・15.1 If a party is prevented from, hindered or delayed in performing any of its obligations under this MTA by reason of a Force Majeure Event, such party shall promptly notify the other of the date of its commencement and the effects of the Force Majeure Event on its ability to perform its obligations under this MTA. If mutually agreed by the parties, then the obligations of the party so affected shall thereupon be suspended for so long as the Force Majeure Event may continue.

・UKBBの条文（英）
  ・15.2 The party affected by a Force Majeure Event shall not be liable for any failure to perform or delay in performing such of its obligations as are prevented, hindered or delayed by the Force Majeure Event provided that such party shall use every reasonable effort to minimise the effects thereof and shall resume performance as soon as possible after the removal of such Force Majeure Event. If the period of non-performance exceeds 90 days from the start of the Force Majeure Event then the non-affected party shall have the option, by written notice to the other party, to terminate this MTA by giving thirty (30) days’ written notice to the other party.

・UKBBの条文（英）
  ・15.3 The provisions of this clause 15 shall not affect any other right which any party may have to terminate this MTA.

・UKBBの条文（英）
  ・16 . Dispute resolution

・UKBBの条文（英）
  ・16.1 If a Dispute arises, the parties shall follow the procedure set out in this clause 16.

・UKBBの条文（英）
  ・16.2 Either party may give the other party written notice of a Dispute, setting out its nature and full particulars ("Notice of Dispute"), together with relevant supporting documents. Within five (5) business days of service of the Notice of Dispute, a UK Biobank representative and a representative from the Applicant shall attempt in good faith to resolve such Dispute.

・UKBBの条文（英）
  ・16.3 If for any reason the respective representatives of the parties are unable to resolve the Dispute within ten (10) business days of the Notice of Dispute, then any of the parties involved in the respective Dispute may refer it for discussion by UK Biobank's Principal Investigator and appropriate senior officer(s) of the Applicant. These senior representatives of the parties (or their respective nominees) shall seek to arrange a meeting or telephone, or videoconference call promptly with a view to resolving the Dispute.

・UKBBの条文（英）
  ・16.4 If, following escalation of any Dispute as set out in clause 16.3, UK Biobank's Principal Investigator and appropriate senior officer(s) of the Applicant are for any reason unable to resolve the Dispute within thirty (30) business days of it being escalated to them, then the parties agree to enter into mediation in good faith the settle the Dispute in accordance with the Centre for Effective Dispute Resolution (CEDR) Model Mediation Procedure. Unless otherwise agreed between the parties within 20 business days of service of the Notice of Dispute, the mediator shall be nominated by CEDR. To initiate the mediation, a party must serve notice in writing to the other party to the Dispute, referring the Dispute to mediation.

・UKBBの条文（英）
  ・16.5 For avoidance of doubt, Disputes with respect to scientific or technical issues or business decisions, and not legal issues, shall remain with senior representatives to be resolved.

・UKBBの条文（英）
  ・16.6 If the Dispute is not settled by mediation within 10 business days of commencement of mediation or within such further period as the parties may agree in writing, either party may issue court proceedings in accordance with clause 17.10 of this MTA.

・UKBBの条文（英）
  ・16.7 Nothing in this clause 16 shall serve to prevent any of the parties from seeking interim/injunctive relief to protect its rights and interests in any court of England and Wales; provided that such relief shall not prevent or stay any mediation.

・UKBBの条文（英）
  ・17 . General

・UKBBの条文（英）
  ・17.1 The parties agree that the Applicant may change the Applicant PI at any time, and from time to time, by written notice to UK Biobank provided that the Applicant ensures that the identity/status of the new Applicant PI is compliant with UK Biobank’s access criteria, access procedures and the relevant terms of this MTA.

・UKBBの条文（英）
  ・17.2 This MTA governs and constitutes the entire agreement between the parties and supersedes, replaces and extinguishes all previous agreements, promises, assurances, warranties, representations and understandings between them (whether oral or written) relating to the subject matter hereof. Further, each party acknowledges and agrees that it does not rely on, and shall have no remedy in respect of, any statement, promise, assurance, statement, warranty, undertaking or representation made (whether innocently or negligently) by the other party or any other person except as expressly set out in this MTA in respect of which its sole remedy shall be for breach of contract.

・UKBBの条文（英）
  ・17.3 If there is any conflict between the provisions of this MTA and any of the Annexes, then the provisions of the relevant Annex shall apply.

・UKBBの条文（英）
  ・17.4 A waiver, delay or forbearance by any party, whether express or implied, in enforcing or exercising any of its rights or remedies hereunder shall not constitute a waiver of such right or remedy, unless set forth in a writing signed by the waiving party.

・UKBBの条文（英）
  ・17.5 No provision of this MTA is intended to be enforceable by any person who is not a party to this MTA and nor are any rights granted to any third party under statute or otherwise.

・UKBBの条文（英）
  ・17.6 Nothing in this MTA shall create a partnership, joint venture or relationship of agency among the parties.

・UKBBの条文（英）
  ・17.7 All variations to this MTA must be agreed, set out in writing and signed on behalf of the parties before they take effect.

・UKBBの条文（英）
  ・17.8 If any provision or part-provision of this MTA is or becomes invalid, illegal or unenforceable, it shall be deemed deleted, but that shall not affect the validity and enforceability of the rest of this MTA.

・UKBBの条文（英）
  ・17.9 If any provision or part-provision of this MTA is deemed deleted under clause 17.8, the parties shall negotiate in good faith to agree a replacement provision that, to the greatest extent possible, achieves the intended commercial result of the original provision.

・UKBBの条文（英）
  ・17.10 This MTA and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the laws of England and Wales. Subject to clause 16 above, the parties irrevocably agree that the English courts shall have exclusive jurisdiction over any suit, action, proceedings or dispute arising out of, or in connection with this MTA or its subject matter or formation.


---


（UKBBに対応しなかったEGA条文の対応関係）

・EGAの条文（英）
  ・1 . The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I.

・EGAの条文（英）
  ・3 . The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification.

・EGAの条文（英）
  ・4 . The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction.

・EGAの条文（英）
  ・5 . The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data.

・EGAの条文（英）
  ・6 . The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipients use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data.

・EGAの条文（英）
  ・7 . The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data.

・EGAの条文（英）
  ・8 . The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data.

・EGAの条文（英）
  ・9 . The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data.

・EGAの条文（英）
  ・10 . The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf).

・EGAの条文（英）
  ・11 . The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements.

・EGAの条文（英）
  ・12 . The User Institution will notify XXXXX within 30 days of any changes or departures of Authorised Personnel.

・EGAの条文（英）
  ・13 . The User Institution will notify XXXXX prior to any significant changes to the protocol for the Project.

・EGAの条文（英）
  ・14 . The User Institution will notify XXXXX as soon as it becomes aware of a breach of the terms or conditions of this agreement.

・EGAの条文（英）
  ・15 . XXXXX may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements.

・EGAの条文（英）
  ・16 . The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than XXXXX. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement.

・EGAの条文（英）
  ・17 . If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement.

・EGAの条文（英）
  ・18 . The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement.

・EGAの条文（英）
  ・19 . This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts. * Agreed for User Institution * Signature: * Name: * Title: * Date: * Principal Investigator * I confirm that I have read and understood this Agreement. * Signature: * Name: * Title: * Date: * Agreed for XXXXX * Signature: * Name: * Title: * Date: * APPENDIX I DATASET DETAILS * Dataset reference (EGA Study ID and Dataset Details) * Name of project that created the dataset * Names of other data producers/collaborators * Specific limitations on areas of research * Minimum protection measures required * File access: Data can be held in unencrypted files on an institutional compute system, with Unix user group read/write access for one or more appropriate groups but not Unix world read/write access behind a secure firewall. * Laptops holding these data should have password protected logins and screenlocks (set to lock after 5 min of inactivity). * If held on USB keys or other portable hard drives, the data must be encrypted. * APPENDIX II PROJECT DETAILS * Details of dataset requested i.e., EGA Study and Dataset Accession Number * Brief abstract of the Project in which the Data will be used (500 words max) * All Individuals who the User Institution to be named as registered users * | Name of Registered User | Email | Job Title | Supervisor* | |---|---|---|---| | | | | | | | | | | * All Individuals that should have an account created at the EGA * | Name of Registered User | Email | Job Title | |---|---|---| | | | | | | | | * APPENDIX III PUBLICATION POLICY * XXXXX intend to publish the results of their analysis of this dataset and do not consider its deposition into public databases to be the equivalent of such publications. * XXXXX anticipate that the dataset could be useful to other qualified researchers for a variety of purposes. However, some areas of work are subject to a publication moratorium. * The publication moratorium covers any publications (including oral communications) that describe the use of the dataset. * For research papers, submission for publication should not occur until XX months after these data were first made available on the relevant hosting database, unless XXXXX has provided written consent to earlier submission. * In any publications based on these data, please describe how the data can be accessed, including the name of the hosting database (e.g., The European Genome-phenome Archive at the European Bioinformatics Institute) and its accession numbers (e.g., EGAS00000000029), and acknowledge its use in a form agreed by the User Institution with XXXXX.


---


（UKBBにもEGAにも対応しなかったNIH条文）

・NIHの条文（英）
  ・1 . Permitted Uses of Data * a. Registry hereby grants to Researcher the right to access and use the Data for the purpose expressly set forth in this Agreement. * b. Researcher shall use the Data solely to perform the Research (and related activities) described in Exhibit B attached to this Agreement (the "Research"). Any other uses are strictly prohibited without the express prior written permission of Registry. To conduct additional or different research, Researcher must submit a separate proposal to Registry. Any such additional/different research must be approved by Registry and set forth in either an amendment to this Agreement or a subsequent data use agreement with Registry. * c. Researcher shall perform the Research and use the Data in strict compliance with: (i) this Agreement; (ii) all applicable laws, rules and regulations (including but not limited to the Health Insurance Portability and Accountability Act of 1996 and all regulations implements thereunder, ("HIPAA"); (iii) all Registry policies, procedures, and governance documents made available to Researcher; (iv) all regulatory approval documents (including but not limited to approvals of Institutional Review Boards ("IRBs"), patient informed consent forms, and patient HIPAA authorization forms; and (v) any documentation submitted by Researcher to Registry in order to gain access to the Data (e.g., Data access request forms, Research proposals). * d. Researcher shall be responsible for performing the Research, overseeing Research personnel and for overall compliance with this Agreement. Registry shall have no obligations with respect to any aspects of the Research. * e. Researcher shall use appropriate safeguards to prevent use or disclosure of the Data other than as provided by this Agreement. Researcher shall notify Registry within [may consider inserting a specific timeframe, e.g., two (2) business days, or a more general requirement, e.g., immediately/promptly upon discovery] of any uses or disclosures of Data not permitted by this Agreement. * f. To the extent applicable, Researcher shall obtain and maintain throughout the Research the relevant IRB's permission to use the Data for purposes of the Research. Researcher shall provide Registry with all written evidence of such IRB approvals upon request. * g. Researcher may make available the Data only to those persons expressly identified as Research personnel in Exhibit B. Any other personnel may require an amendment to this Agreement or a separate data use agreement with Registry. * h. Registry (or its agents) may audit Researcher's use of the Data to ensure compliance with this Agreement. Any such audits will be conducted during Researcher's regular business hours with reasonable advanced notice and consideration for Researcher's business operations. Researcher will cooperate, and will ensure that all Researcher personnel will cooperate, with the auditors and will make all records and materials available to them. * i. [May consider inserting other restrictions that may be desirable, e.g., prohibitions on using the Data for specific purposes, use of Data within specific geographic locations only]

・NIHの条文（英）
  ・2 . Cost Jor No Cost * a. Registry is making the Data available to Researcher at no cost to Researcher. [If payment is desired, it may be beneficial to add payment terms, e.g., invoicing procedure, payment due dates]. * b. Researcher bears all costs and expenses incurred by Researcher to access and use the Data, and conduct the Research.

・NIHの条文（英）
  ・3 . Representations of Researcher * a. Researcher represents and warrants that (i) it is duly incorporated or organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization; (ii) it has the power, authority and legal right to enter into this Agreement and to perform the activities contemplated hereunder, and that it has taken all necessary corporate action to authorize execution of this Agreement to the extent required; (iii) it has obtained or will obtain, to the extent required, all necessary consents, approvals and authorizations of governmental or regulatory authorities required to be obtained related to the performance of this Agreement and the Research; and (iv) the execution and delivery of this Agreement will not conflict with or violate any requirement of any applicable law or regulation and does not conflict with or constitute a default under any contractual obligation enforceable against it. * b. [Depending on the nature of the Data, it may be advisable to add detailed security requirements for Researcher to follow, e.g., use of encryption, password security requirements, separation of Data from other datasets, linking Data with other datasets. Security requirements also may be set forth in a Registry policy cross-referenced here].

・NIHの条文（英）
  ・5 . Indemnification * [May consider including indemnification language (e.g., "Researcher shall indemnify, defend, and hold harmless Registry and its officers, employees, agents, and representatives from and against any and all claims, damages, losses, fees, expenses, and liability arising from use of the Data."];

・NIHの条文（英）
  ・6 . Disclaimer * [May consider including a disclaimer of warranties related to the accuracy, integrity, reliability, or completeness of data, as well as a disclaimer of standard warranties of title, non- infringement, merchantability, fitness for a particular purpose. May also consider adding language so it is clear that underlying registry data contributors have no responsibilities regarding the Data.]

・NIHの条文（英）
  ・9 . Publications * a. [Registry may insert its desired publication requirements or otherwise attach or cross-reference its policy governing publications]. * b. [Registry may consider adding specific attribution requirements, to ensure that all references of Registry as the source of Data are accurate and consistent in any publications].

・NIHの条文（英）
  ・10 . Miscellaneous * [Registry may consider adding customary contract boilerplate, such as clauses related to assignment, notices, survival, counterparts, force majeure.] * IN WITNESS WHEREOF, the duly authorized representatives of the parties hereto have executed this Agreement as of the Effective Date. * REGISTRY * By: * Print Name: * Title: * Date: * RESEARCHER * By: * Print Name: * Title: * Date: * EXHIBIT A * Data * [May consider adding: (i) description of the Data being shared; (ii) format of the Data; (iii) method of Data delivery; (iv) classification of the Data (e.g., de-identified data)]; (v) any specific restrictions on Data usage depending on the nature of the Data (e.g., can Data be used for commercial purposes, is use of the Data limited to academic endeavors, can Researcher benchmark/compare the Data with its own data).